NEW YORK – Pfizer’s COVID-19 vaccine is believed to be effective in adolescents.

The pharmaceutical company says clinical trial results showed 100 percent efficacy in youths ages 12 to 15.

Results also found the age group tolerated the doses well.

Researchers say there were no COVID-19 cases among the more than one thousand participants given the vaccine. The data has yet to be peer reviewed.

Pfizer is planning to submit its results to the Food and Drug Administration as soon as possible to expand the emergency use authorization.

The COVID-19 vaccine is currently authorized in the U.S. for people ages 16 and older.